Holen Sie sich die Stockscreener-App
88.37
8.91%
-8.64
Handel nachbörslich:
88.37
Schlusskurs vom Vortag:
$97.01
Offen:
$91.8
24-Stunden-Volumen:
268.28K
Relative Volume:
0.81
Marktkapitalisierung:
$1.30B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-130.19M
KGV:
-10.53
EPS:
-8.3898
Netto-Cashflow:
$-131.94M
1W Leistung:
-0.33%
1M Leistung:
-5.19%
6M Leistung:
+16.58%
1J Leistung:
+269.13%
1-Tages-Spanne:
$87.01
$96.06
1-Wochen-Bereich:
$87.01
$101.00
52-Wochen-Spanne:
$22.40
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
88.37 | 1.44B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - Stock Traders Daily
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - marketbeat.com
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - marketbeat.com
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Inhibrx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data - Stock Titan
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart - Stock Titan
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold" - marketbeat.com
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday - marketbeat.com
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX - marketbeat.com
Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800 - TradingKey
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P. - marketbeat.com
TradingKey - TradingKey
Inhibrx Biosciences Inc (INBX) Balance Sheet - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile? - Sahm
Inhibrx Biosciences (INBX) Faces Headwinds as Stock Dips 1.89% – Support Test AheadChandelier Stop - dars.gov.et
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
Inhibrx expands credit facility to $500 million with Oxford - Investing.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
Inhibrx Gets $100 Million Now; Lenders May Fund $225 Million More - Stock Titan
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Are you looking for a top momentum pick? Why Inhibrx Biosciences, Inc. (INBX) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):